

Isonics Corporation Signs Agreement to Produce New U.S. Supply of Indium-111 High-Value Biomedical Isotope

Isotopes are a part of everyday business and they go a long way towards improving our quality of life.

Yahoo News
June 14, 2005

Isonics Corporation committed to the development of next-generation technology for the homeland security and semiconductor markets, announced the execution of an Agreement with Central Radiopharmaceutical Services, Inc. (CRS) for the joint production and marketing of Indium-111, an isotope used in the diagnosis of cancer and other medical conditions. Lindsay A. Gardner, Vice President of Isonics' Life Sciences Division, made the announcement.

CRS is an advanced biomedical research and development facility established by the State University of New York at Buffalo. The agreement with CRS is designed to enable Isonics' Life Sciences Division to increase its capacity to produce a variety of high-value isotopes and other products, and to expand its business and revenue within the Company's Life Sciences Division.

"While successfully serving our customers for many years from our overseas producers, several of our customers asked us to consider producing shorter lived, higher value-added products in the U.S.," said Ms. Gardner. "After searching for and evaluating potential partners, we are pleased to select CRS as an alliance partner. CRS brings not only the R&D expertise through their relationship with the State University of New York at Buffalo, but also the commercial savvy necessary to be successful in the biomedical marketplace."

The alliance's initial product is Indium-111, a radioisotope produced from the stable isotope cadmium-112. CRS will provide irradiation facilities/expertise and chemical syntheses using Isonics-provided methodologies. Indium-111 is used in specialized diagnostic and therapeutic applications in nuclear medicine, for example, as a diagnostic agent for prostate cancer and labeling of platelets for thrombus (blood clot) detection. Other radiochemicals are under consideration for production in the future. Initial commercial quantities of Indium-111 are expected in fourth calendar quarter 2005. Isonics and CRS have been developing new manufacturing methods over the past 6 months.